Comments

Immatics Stock Price, Quotes and Forecasts

Q: What sector and industry does Immatics (IMTX) operate in?

Immatics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

IMTXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$5.94

-0.06-1.00%

At close: -

$5.90

-0.04-0.67%

After Hours: 7:01 PM EDT

Immatics (IMTX) Forecast

News Earnings Immatics (IMTX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Immatics Stock Price, Quotes and Forecasts | NASDAQ:IMTX | Benzinga

Explore Immatics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IMTX.

Open	$5.97
Close	$5.94
Volume / Avg.	494.20K / 678.18K
Day Range	$5.83 - $6.16
52 Wk Range	3.30 - 13.70
Market Cap	$717.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	63
Short Interest	5.07%
Days to Cover	8.35

Recent News

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits shown. Phase 3 trials are set to begin by December 2024.

Vandana Singh

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

Zacks

United Therapeutics Q2 Earnings Lag, Sales Top Estimates

United Therapeutics‘ (NASDAQ: UTHR) second-quarter 2024 earnings of $5.85 per share missed the Zacks Consensus Estimate of $6.33. Earnings rose 12% year over year on the back of higher product sales.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Apr

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$5.97
Close	$5.94
Volume / Avg.	494.20K / 678.18K
Day Range	$5.83 - $6.16
52 Wk Range	3.30 - 13.70
Market Cap	$717.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	63
Short Interest	5.07%
Days to Cover	8.35

About Immatics N.V

Sector

Health Care

Industry

Biotechnology

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Immatics (IMTX) stock?

You can purchase shares of Immatics (NASDAQ:IMTX) through any online brokerage.

View our list of the best stock brokerages

Who are Immatics (IMTX) competitors?

Other companies in Immatics’s space includes: Immunome (NASDAQ:IMNM), KalVista Pharma (NASDAQ:KALV), Gyre Therapeutics (NASDAQ:GYRE), Cogent Biosciences (NASDAQ:COGT) and Upstream Bio (NASDAQ:UPB).

What is the forecast, or price target, for Immatics (IMTX) stock?

Immatics has a consensus price target of $17.00.

What is the current price for Immatics (IMTX)?

The stock price for Immatics (NASDAQ: IMTX) is $5.9 last updated June 10, 2025 at 7:01 PM EDT.

Does Immatics (IMTX) pay a dividend?

There are no upcoming dividends for Immatics.

When is Immatics (NASDAQ:IMTX) reporting earnings?

Immatics’s Q2 earnings are confirmed for Tuesday, August 12, 2025.

Is Immatics (IMTX) going to split?

There is no upcoming split for Immatics.

What sector and industry does Immatics (IMTX) operate in?

Immatics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.